MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, COYA had $8,483,024 increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$8,483,024
Unit: Dollar
Positive Cash Flow Breakdown
    • Proceeds from sale of common sto...
    • Collaboration revenue
    • Stock-based compensation, includ...
    • Others
Negative Cash Flow Breakdown
    • In-process research and developm...
    • Purchase of in-process research ...
    • Accounts payable
    • Others

Cash Flow
2025-12-31
Collaboration revenue
7,945,753
Total research and development expenses
16,734,549
In-process research and development
2,289,602
Total general and administrative expenses
11,449,466
Depreciation
27,361
Other income
1,332,207
Pre-tax loss
-21,223,018
Income tax benefit
3,089
Net loss
-21,226,107
Depreciation
27,361
Stock-based compensation, including the issuance of restricted stock
4,290,315
Acquired in-process research and development
2,289,602
Prepaids and other current assets
-2,852,434
Accounts payable
-527,006
Accrued expenses
1,099,853
Deferred collaboration revenue
454,247
Net cash used in operating activities
-10,739,301
Purchase of in-process research and development assets
1,164,602
Net cash used in investing activities
-1,164,602
Proceeds from sale of common stock, net of offering costs
20,348,653
Proceeds from the exercise of stock options
38,274
Net cash provided by financing activities
20,386,927
Net increase in cash and cash equivalents
8,483,024
Cash and cash equivalents as of beginning of the year
38,339,762
Cash and cash equivalents as of end of the year
46,822,786
Unit: Dollar.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from sale ofcommon stock, net of...$20,348,653 Proceeds from theexercise of stock options$38,274 Net cash provided byfinancing activities$20,386,927 Net increase in cashand cash...$8,483,024 Canceled cashflow$11,903,903 Stock-based compensation,including the issuance of...$4,290,315 Prepaids and othercurrent assets-$2,852,434 Acquired in-processresearch and development$2,289,602 Accrued expenses$1,099,853 Deferred collaborationrevenue$454,247 Depreciation$27,361 Net cash used inoperating activities-$10,739,301 Net cash used ininvesting activities-$1,164,602 Canceled cashflow$11,013,812 Net loss-$21,226,107 Purchase of in-processresearch and development...$1,164,602 Accounts payable-$527,006 Collaboration revenue$7,945,753 Other income$1,332,207 Pre-tax loss-$21,223,018 Income tax benefit$3,089 Canceled cashflow$9,277,960 Total research anddevelopment expenses$16,734,549 Total general andadministrative expenses$11,449,466 In-process research anddevelopment$2,289,602 Depreciation$27,361

Coya Therapeutics, Inc. (COYA)

Coya Therapeutics, Inc. (COYA)